• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    68 Biggest Movers From Yesterday

    4/19/22 4:35:35 AM ET
    $ADXN
    $AGRI
    $APCX
    $ARQQ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Metal Fabrications
    Industrials
    Get the next $ADXN alert in real time by email

    Gainers

    • Casa Systems, Inc. (NASDAQ:CASA) shares surged 82.5% to close at $7.10 on Monday after the company announced a multi-year contract with Verizon to provide 5G core network functions.
    • Enservco Corporation (NASDAQ:ENSV) climbed 38% to settle at $3.63 on Monday. Enservco delayed filing of Form 10-K to restate 2021 Form 10-Qs to account for company's utilization of deferred tax liabilities.
    • Frequency Therapeutics, Inc. (NASDAQ:FREQ) gained 30.8% to close at $1.91 on above-average volume.
    • Natus Medical Incorporated (NASDAQ:NTUS) rose 28.6% to close at $33.51 after the company announced it will be acquired by ArchiMed Group for $33.50 per share in cash.
    • BitNile Holdings, Inc. (NYSE:NILE) climbed 28.6% to close at $0.7070 following a 5% decline on Thursday.
    • Iveda Solutions, Inc. (NASDAQ:IVDA) jumped 21.5% to settle at $2.54 after the company announced a strategic partnership agreement with IP Dream. The company received a $1.3 million purchase order for 50 units of its Utilus smart pole as IP Dream's initial order.
    • Camber Energy, Inc. (NYSE:CEI) gained 20.7% to close at $1.05 after gaining over 5% on Thursday.
    • China Liberal Education Holdings Limited (NASDAQ:CLEU) gained 20% to close at $1.50.
    • IMARA Inc. (NASDAQ:IMRA) gained 19.2% to settle at $1.24.
    • Brickell Biotech, Inc. (NASDAQ:BBI) surged 18.6% to close at $0.3520.
    • MoonLake Immunotherapeutics (NASDAQ:MLTX) gained 18.6% to settle at $5.99.
    • IT Tech Packaging, Inc. (NYSE:ITP) rose 18.5% to close at $0.25. IT Tech Packaging, last month, reported fourth-quarter FY21 sales growth of 38.7% year-on-year, to $45.1 million versus $32.48 million last year.
    • Aterian, Inc. (NASDAQ:ATER) jumped 18.4% to close at $6.55 on above-average volume Monday.
    • AgriFORCE Growing Systems, Ltd. (NASDAQ:AGRI) shares climbed 18.1% to close at $2.61.
    • Maris-Tech Ltd. (NASDAQ:MTEK) jumped 16.7% to settle at $1.54.
    • EuroDry Ltd. (NASDAQ:EDRY) gained 16.5% to close at $36.00.
    • Aziyo Biologics, Inc. (NASDAQ:AZYO) gained 14.4% to settle at $7.41.
    • Addex Therapeutics Ltd (NASDAQ:ADXN) jumped 14.2% to close at $5.01.
    • Wrap Technologies, Inc (NASDAQ:WRAP) gained 13.3% to settle at $2.89 after the company announced a CEO appointment.
    • Kaival Brands Innovations Group, Inc. (NASDAQ:KAVL) rose 13.2% to settle at $1.37. Kaival Brands Innovations Group expanded its wholesaler and retailer distribution accounts for Bidi Vapor LLC, which are expected to reach 28,000 additional stores.
    • Cyren Ltd. (NASDAQ:CYRN) gained 12.9% to settle at $2.71.
    • Tritium DCFC Limited (NASDAQ:DCFC) rose 12.2% to close at $9.56 after the company announced a multi-year contract with BP for the supply of chargers and related services to support BP's global EV charging network.
    • Concord Medical Services Holdings Limited (NYSE:CCM) gained 11.8% to close at $1.90.
    • Zovio Inc (NASDAQ:ZVO) gained 11.5% to close at $0.7805 after the company reported Q4 earnings results on April 15th.
    • CEL-SCI Corporation (NYSE:CVM) rose 11.2% to close at $3.67.

     

    Don’t forget to check out our premarket coverage here .


    Losers

    • Cypress Environmental Partners, L.P. (NYSE:CELP) fell 48% to settle at $0.77 on Monday after the company reported Q4 earnings results on April 15th.
    • Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) dropped 34.5% to close at $0.1711 after the company announced a 1-for-50 reverse stock split.
    • Nutex Health, Inc. (NASDAQ:NUTX) fell 29.2% to settle at $5.17 on below-average volume.
    • Digital Brands Group, Inc. (NASDAQ:DBGI) dropped 23.9% to close at $0.8522 amid overall market weakness as a rise in bond-yields weighs on stocks.
    • Nektar Therapeutics (NASDAQ:NKTR) shares dipped 23.1% to close at $4.74 on Monday. Nektar Therapeutics and Bristol Myers Squibb Co jointly decided to end the global clinical development program for bempegaldesleukin in combination with Opdivo. Goldman Sachs downgraded Nektar Therapeutics from Neutral to Sell and announced a $3 price target.
    • InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) dropped 22.3% to close at $0.2344 after the company announced a reverse stock split.
    • TG Therapeutics, Inc. (NASDAQ:TGTX) fell 21.8% to close at $6.92 after the company announced it has voluntarily withdrawn the BLA/sNDA for U2 for the treatment of adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
    • Revelation Biosciences, Inc. (NASDAQ:REVB) declined 21% to close at $0.7505.
    • Veru Inc. (NASDAQ:VERU) dropped 20.4% to close at $11.90.
    • Gaucho Group Holdings, Inc. (NASDAQ:VINO) fell 20.3% to close at $1.92. Gaucho Group recently reported FY21 revenues of $4.9 million.
    • Genius Group Limited (NYSE:GNS) fell 20.1% to close at $6.35.
    • Engine Gaming and Media, Inc. (NASDAQ:GAME) fell 19.8% to close at $1.50.
    • Helbiz, Inc. (NASDAQ:HLBZ) fell 19.6% to close at $2.14.
    • AppTech Payments Corp. (NASDAQ:APCX) fell 19.6% to close at $1.81.
    • Gogoro Inc. (NASDAQ:GGR) dipped 19.2% to close at $8.00.
    • Viracta Therapeutics, Inc. (NASDAQ:VIRX) dipped 18.7% to close at $3.30.
    • DiDi Global Inc. (NYSE:DIDI) fell 18.3% to close at $2.01 after the company announced a shareholders meeting to vote on voluntarily delisting the company's American Depositary Shares from the New York Stock Exchange. DiDi Global said its total revenue dropped to 40.8 billion yuan ($6.40 billion) for the quarter ended Dec. 31, 2021, down from 46.7 billion yuan in the year-ago period.
    • Sharps Technology, Inc. (NASDAQ:STSS) declined 18% to settle at $1.73. The company recently priced its IPO at $4.25 per share.
    • Guardforce AI Co., Limited (NASDAQ:GFAI) dipped 17.7% to close at $0.7423.
    • Arqit Quantum Inc. (NASDAQ:ARQQ) fell 17.1% to settle at $12.49.
    • Mersana Therapeutics, Inc. (NASDAQ:MRSN) dipped 16.9% to close at $4.08. Mersana Therapeutics Director Andrew Hack recently reported the purchase of 598,086 shares at an average price of $4.18/share.
    • Biodesix, Inc. (NASDAQ:BDSX) fell 16.5% to close at $1.3450
    • Immunome, Inc. (NASDAQ:IMNM) fell 16.3% to settle at $4.31. Immunome, last month, posted a Q4 loss of $0.65 per share.
    • Generation Bio Co. (NASDAQ:GBIO) declined 16.2% to close at $7.89.
    • MiNK Therapeutics, Inc. (NASDAQ:INKT) fell 15.7% to settle at $2.47.
    • UserTesting, Inc. (NYSE:USER) dropped 15.6% to close at $8.80.
    • Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) fell 15.3% to close at $1.33. LIXTE Biotechnology recently announced a $5.8 million registered direct offering priced at-the-market.
    • SCWorx Corp. (NASDAQ:WORX) declined 15.3% to close at $0.9482.
    • Cyteir Therapeutics, Inc. (NASDAQ:CYT) dropped 15% to settle at $3.18. Cyteir Therapeutics, last month, reported better-than-expected Q4 EPS results.
    • Mullen Automotive, Inc. (NASDAQ:MULN) shares fell 14.8% to close at $1.84. Mullen Automotive plans to start Electric Vehicle battery pack production in its research & development facility in California.
    • Pyxis Oncology, Inc. (NASDAQ:PYXS) dropped 14.5% to settle at $3.12.
    • Vince Holding Corp. (NYSE:VNCE) fell 14.4% to close at $7.49.
    • Alaunos Therapeutics, Inc. (NASDAQ:TCRT) dropped 14.3% to close at $0.4103. Alaunos Therapeutics recently posted Q4 loss of $0.05 per share.
    • Sunshine Biopharma, Inc. (NASDAQ:SBFM) declined 14.1% to settle at $3.46.
    • Histogen Inc. (NASDAQ:HSTO) dropped 13.7% to close at $0.2129.
    • OpGen, Inc. (NASDAQ:OPGN) fell 13.7% to settle at $0.6557.
    • Cardiol Therapeutics Inc. (NASDAQ:CRDL) dropped 13.2% to close at $1.78.
    • MedAvail Holdings, Inc. (NASDAQ:MDVL) shares fell 11.5% to close at $2.16 after surging around 70% on Thursday. Ally Bridge Group recently reported a purchase of roughly 21.176 million shares of MedAvail Holdings for an average price of $1.06 per share.
    • Dada Nexus Limited (NASDAQ:DADA) fell 11% to close at $8.17.
    • WeWork Inc. (NYSE:WE) fell 11% to close at $5.93.
    • The Charles Schwab Corporation (NYSE:SCHW) dropped 9.4% to close at $74.94 after the company reported worse-than-expected Q1 EPS and sales results.
    • HDFC Bank Limited (NYSE:HDB) fell 7.9% to close at $54.25.
    • Forge Global Holdings, Inc. (NYSE:FRGE) fell 6.3% to close at $12.70. Forge Global Holdings named James H. Herbert, II to its Board of Directors, effective as of April 12.
    Get the next $ADXN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADXN
    $AGRI
    $APCX
    $ARQQ

    CompanyDatePrice TargetRatingAnalyst
    Veru Inc.
    $VERU
    12/18/2025$25.00Buy
    Canaccord Genuity
    Generation Bio Co.
    $GBIO
    12/16/2025$5.50Neutral → Outperform
    Wedbush
    Generation Bio Co.
    $GBIO
    12/16/2025$5.00Buy → Hold
    Jefferies
    Forge Global Holdings Inc.
    $FRGE
    12/12/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    Charles Schwab Corporation
    $SCHW
    12/11/2025$119.00Buy
    UBS
    Immunome Inc.
    $IMNM
    12/1/2025$36.00Buy
    Truist
    Nektar Therapeutics
    $NKTR
    11/26/2025$102.00Buy
    Citigroup
    Forge Global Holdings Inc.
    $FRGE
    11/7/2025Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $ADXN
    $AGRI
    $APCX
    $ARQQ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Emeritus Director Schuler Jack W bought $1,180,736 worth of shares (100,000 units at $11.81) (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    1/27/26 9:29:02 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Emeritus Director Schuler Jack W bought $903,561 worth of shares (82,465 units at $10.96) (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    1/26/26 9:28:57 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Chief Executive Officer Kersten Geert R bought $200,001 worth of shares (38,023 units at $5.26), increasing direct ownership by 46% to 120,815 units (SEC Form 4)

    4 - CEL SCI CORP (0000725363) (Issuer)

    1/26/26 8:23:27 AM ET
    $CVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADXN
    $AGRI
    $APCX
    $ARQQ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Veru with a new price target

    Canaccord Genuity initiated coverage of Veru with a rating of Buy and set a new price target of $25.00

    12/18/25 9:11:57 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Generation Bio upgraded by Wedbush with a new price target

    Wedbush upgraded Generation Bio from Neutral to Outperform and set a new price target of $5.50

    12/16/25 12:29:16 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Generation Bio downgraded by Jefferies with a new price target

    Jefferies downgraded Generation Bio from Buy to Hold and set a new price target of $5.00

    12/16/25 8:41:52 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $AGRI
    $APCX
    $ARQQ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Wrap Technologies Highlights Clinton County Probation Services' Adoption of WrapReality™ to Advance Non-Lethal Response Training in Corrections

    MIAMI, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Wrap Technologies, Inc. (NASDAQ:WRAP) ("Wrap" or, the "Company"), a global leader in non-lethal response and public safety technology, today highlighted the successful implementation of its WrapReality™ virtual reality platform by Clinton County Probation Services ("Clinton County"), a Pennsylvania-based corrections agency. Led by Ed Hosler, a 20-year probation professional and certified instructor across defensive tactics, firearms, and other tools for law enforcement, Clinton County adopted WrapReality with the goal to enhance realism, improve decision-making under stress, and support consistent Non-Lethal Response training across probation offic

    2/6/26 7:30:00 AM ET
    $WRAP
    Ordnance And Accessories
    Industrials

    TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

    NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held in San Diego, California. Links to each presentation are included below. Michael S. Weiss, Chief Executive Officer and Chairman of TG Therapeutics stated, "We are pleased to share data at this year's ACTRIMS annual meeting, including updates from the ENABLE real world study evaluating patients with RMS on BRIUMVI. Our presentations reflect our continued focus on advancing the clinical understanding of

    2/6/26 7:30:00 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Immunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on February 2, 2026, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 30,000 shares of common stock to one new employee under the Company's 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $

    2/5/26 4:00:00 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $AGRI
    $APCX
    $ARQQ
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

    Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (SUPPL-11) with active ingredient UBLITUXIMAB-XIIY has changed to 'Approval' on 10/30/2024. Application Category: BLA, Application Number: 761238, Application Classification:

    10/31/24 4:38:40 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

    Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (ORIG-1) with active ingredient UBLITUXIMAB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761238, Application Classification:

    12/28/22 12:54:09 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ENTADFI issued to VERU INC

    Submission status for VERU INC's drug ENTADFI (ORIG-1) with active ingredient FINASTERIDE;TADALAFIL has changed to 'Approval' on 12/09/2021. Application Category: NDA, Application Number: 215423, Application Classification: Type 4 - New Combination

    12/13/21 8:12:46 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $AGRI
    $APCX
    $ARQQ
    SEC Filings

    View All

    SEC Form S-8 filed by GameSquare Holdings Inc.

    S-8 - GameSquare Holdings, Inc. (0001714562) (Filer)

    2/6/26 5:02:19 PM ET
    $GAME
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form PRE 14A filed by Revelation Biosciences Inc.

    PRE 14A - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

    2/6/26 4:32:19 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Biodesix Inc.

    S-8 - BIODESIX INC (0001439725) (Filer)

    2/6/26 4:14:20 PM ET
    $BDSX
    Medical Specialities
    Health Care

    $ADXN
    $AGRI
    $APCX
    $ARQQ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-Chairman Schwab Charles R. sold $17,079,953 worth of shares (164,600 units at $103.77) (SEC Form 4)

    4 - SCHWAB CHARLES CORP (0000316709) (Issuer)

    2/5/26 9:24:17 PM ET
    $SCHW
    Investment Bankers/Brokers/Service
    Finance

    SEC Form 4 filed by Interim CEO Civik Thomas

    4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

    2/5/26 8:37:38 PM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Co-Chairman Bettinger Walter W exercised 257,410 shares at a strike of $42.99 and sold $26,778,406 worth of shares (257,410 units at $104.03) (SEC Form 4)

    4 - SCHWAB CHARLES CORP (0000316709) (Issuer)

    2/5/26 7:18:31 PM ET
    $SCHW
    Investment Bankers/Brokers/Service
    Finance

    $ADXN
    $AGRI
    $APCX
    $ARQQ
    Leadership Updates

    Live Leadership Updates

    View All

    NodThera Appoints Geoff McDonough, M.D., as Chief Executive Officer

    Dr. McDonough brings global company-building, commercial strategy, and R&D leadership experience to the Company ahead of key clinical milestones NodThera plans to report results from two Phase 2 cardiometabolic trials RESOLVE-1 and RESOLVE-2 in mid-2026 and third quarter 2026 respectively Company preparing to begin cardiometabolic Phase 3 trial in 1H 2027 BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- NodThera, the leading clinical-stage NLRP3 company developing a portfolio of best-in-class brain-penetrant and immune-targeted oral inhibitors to address unmet needs in cardiometabolic and neuroinflammatory diseases driven by the NLRP3/IL-6/IL-1 inflammation pathway, announced the appointment o

    2/4/26 8:00:00 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity

    BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a leadership transition to continue execution and advancement of the Company's strategic and clinical goals. Thomas Civik, a member of Pyxis Oncology's Board of Directors since the Company's IPO and a highly experienced biotechnology executive with a proven track record in advancing cancer therapeutics, has been appointed Interim Chief Executive Officer, effective immediately. Lara S. Sullivan, M.D., has stepped down from her roles as President, Chief Executive Officer and Chief Medical Officer. With

    2/3/26 6:45:00 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Charles Schwab Corporation Announces Executive Transitions

    The Charles Schwab Corporation (NYSE:SCHW) today announced several executive transitions, including two planned retirements and organizational updates. Charles Schwab Bank Leadership Transition Paul Woolway, CEO of Charles Schwab Bank, will retire on July 1, 2026, after more than 16 years with the company. Tyler Woulfe, Managing Director, Banking & Trust Services, will succeed Woolway as President and CEO of Charles Schwab Bank, effective July 1, 2026, and will report to Neesha Hathi, Managing Director, Wealth Advisory and Banking Services. Internal Audit Leadership Transition Mitch Mantua, General Auditor, also retires on July 1, 2026, after a decade of service. Jessica Bramhall, M

    1/29/26 4:15:00 PM ET
    $SCHW
    Investment Bankers/Brokers/Service
    Finance

    $ADXN
    $AGRI
    $APCX
    $ARQQ
    Financials

    Live finance-specific insights

    View All

    Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th

    MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Wednesday, February 11, 2026, at 8:00 a.m. ET to discuss its fiscal 2026 first quarter financial results and to provide a business update. The audio webcast will be accessible under the Home page and Investors page of the Company's website at www.verupharma.com. To join the conference call via telephone, please dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international) and ask to join the Veru I

    2/4/26 8:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schwab Declares 19% Increase in Quarterly Common Stock Dividend and Declares Preferred Stock Dividends

    The Board of Directors of The Charles Schwab Corporation at its meeting today declared a 5 cent, or 19%, increase in the regular quarterly cash dividend to $0.32 per common share. The dividend is payable February 27, 2026 to stockholders of record as of the close of business on February 13, 2026. Co-Chairman Walt Bettinger commented, "This dividend increase reflects the Board's confidence in our ability to continue to drive profitable growth through-the-cycle as we advance our ‘Through Clients' Eyes' strategy." In addition, the Board of Directors also declared dividends on the following series of outstanding preferred stock, payable March 2, 2026 to stockholders of record as of the clos

    1/29/26 4:18:00 PM ET
    $SCHW
    Investment Bankers/Brokers/Service
    Finance

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, Jan. 22, 2026 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH.  Fund Ticker Distribution Per Share Distribution Rate 30-Day SEC Yield Return of Capital Ex-Date / Record Date Payment Date 1-Month Return 1-Year Return Since InceptionReturn Bitwise COIN Option Income Strategy ETF ICOI $0.50284 36.87 % 0.00 % 50.00 % 01/23/2026 01/27/2026 -4.93 % N/A -10.58 % Bitwise MARA Option Income Strategy ETF IMRA $0.20782 14

    1/22/26 4:21:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADXN
    $AGRI
    $APCX
    $ARQQ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Arqit Quantum Inc.

    SC 13D/A - Arqit Quantum Inc. (0001859690) (Subject)

    12/13/24 8:03:28 PM ET
    $ARQQ
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13G/A filed by Maris-Tech Ltd.

    SC 13G/A - Maris Tech Ltd. (0001872964) (Subject)

    12/13/24 11:34:57 AM ET
    $MTEK
    Telecommunications Equipment
    Telecommunications

    Amendment: SEC Form SC 13D/A filed by Kaival Brands Innovations Group Inc.

    SC 13D/A - Kaival Brands Innovations Group, Inc. (0001762239) (Subject)

    12/12/24 7:22:30 PM ET
    $KAVL
    Other Consumer Services
    Consumer Discretionary